| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 30.10.2018 og
angivet som gældende fra 28.10.2018 (2014
dage). |
Ingen historik.
| Branche | | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
| Sidst opdateret den 30.10.2018 og
angivet som gældende fra 28.10.2018 (2014
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 08.07.2021 og
angivet som gældende fra 08.07.2021 (1030
dage). |
| Historik | Start | Stop |
|---|
| false | 08.07.2021 | |
| true | 28.10.2018 | 07.07.2021 |
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | Blue Cell Therapeutics ApS. |
| Sidst opdateret den 25.06.2020 og
angivet som gældende fra 30.03.2020 (1495
dage). |
| Historik | Start | Stop |
|---|
| Blue Cell Therapeutics ApS | 30.03.2020 | |
| Regenerative Therapeutics IVS | 28.10.2018 | 29.03.2020 |
| Binavne | | ADRC Therapeutics ApS. |
| Sidst opdateret den 25.06.2020 og
angivet som gældende fra 30.03.2020 (1495
dage). |
| Historik | Start | Stop |
|---|
| ADRC Therapeutics ApS | 30.03.2020 | |
| Pecam Therapeutics ApS | 30.03.2020 | |
| Stem Therapy ApS | 30.03.2020 | |
| StemCell Dynamics ApS | 30.03.2020 | |
| StemCell Evolution ApS | 30.03.2020 | |
| ADRC Therapeutics IVS | 28.10.2018 | 29.03.2020 |
| Pecam Therapeutics IVS | 28.10.2018 | 29.03.2020 |
| Stem Therapy IVS | 28.10.2018 | 29.03.2020 |
| StemCell Dynamics IVS | 28.10.2018 | 29.03.2020 |
| StemCell Evolution IVS | 28.10.2018 | 29.03.2020 |
| Tegningsregel | | Selskabet tegnes af den administrerende direktør, den administrerende direktør i forening
med et bestyrelsesmedlem eller af den samlede bestyrelse. |
| Sidst opdateret den 16.07.2021 og
angivet som gældende fra 08.02.2019 (1911
dage). |
| Fortolkning
(3 tegningsmuligheder)
| | direktøren |
| direktøren + 1 bestyrelsesmedlem |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af den administrerende direktør, den administrerende direktør i forening
med et bestyrelsesmedlem eller af den samlede bestyrelse | 08.02.2019 | |
| Selskabet tegnes af den administrerende direktør | 28.10.2018 | 07.02.2019 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Grant Thornton, Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:34209936
Beskrivelse af revisor:statsautoriseret revisor
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for Opinion
We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Blue Cell Therapeutics ApS for the financial year 1 January - 31 December 2022, which comprise income statement, balance sheet, statement of changes in equity, notes and a summary of significant accounting policies, for the Company. The financial statements are prepared under the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022, and of the results of the Company's operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on Management’s Review
Management is responsible for Management’s Review.
Our opinion on the financial statements døs not cover Management’s Review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that Management’s Review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of Management’s Review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration